# Cerebrolysin

> Source: https://peptidestogo.com/peptides/cerebrolysin/
> Last updated August 23, 2026 · PeptidesToGo Editorial Team · Educational, not medical advice

Porcine brain peptide complex

**Status:** Not FDA-approved · no US pharmacy route

**How it is delivered:** Injection — a course of daily infusions, in countries where it is licensed.

Cerebrolysin is not a molecule. It is a defined mixture — low-molecular-weight peptides, roughly a quarter of the active fraction, and free amino acids making up the rest — produced by controlled enzymatic breakdown of purified porcine brain tissue by EVER Neuro Pharma in Austria. There is no structural formula, which is why there are no generics: the FDA’s own substance registry files it as structurally diverse, and its identity is defined by the manufacturing process rather than by a diagram.

The peptide fraction is where the proposed activity sits. Assays detect fragments resembling several of the body’s own neurotrophic factors — NGF, BDNF, CNTF, GDNF — and none of them are the full proteins, which would be too large to survive processing or to cross into the brain. The best-characterized pathway is TrkB activation, the same receptor BDNF works through, which suppresses the machinery of cell death and raises survival proteins. A second proposed action is indirect: nudging the patient’s own neurons and glia into making more native neurotrophic factor themselves.

> Forty years of use, seven Cochrane reviews, and the same verdict each time — a plausible mechanism, a clean safety record, and an efficacy signal that gets stronger the sicker the patient was to begin with.

That last part is the crux. CASTA, the largest stroke trial at 1,070 patients, missed its primary endpoint; the benefit showed up in a subgroup with more severe baseline strokes. One reading is that mild strokes recover regardless, so there is no room for a drug to show anything, and pooling dilutes responders with patients who were always going to be fine. The other reading is that a subgroup finding in a trial that missed its endpoint is exactly the kind of result that does not replicate. Both readings are live. For the trial-by-trial record and the methodological objections, read the deep-dive on PeptideWellness.

Last updated August 23, 2026 · PeptidesToGo Editorial Team ·
[Educational, not medical advice](https://peptidestogo.com/legal/medical-disclaimer/)

## Who it's for (or who should avoid)

### What it's aimed at

Where it is licensed, cerebrolysin is used as adjunctive therapy — added to standard care rather than replacing it:

- **Acute ischaemic stroke** — started within hours of onset, alongside or after thrombolysis, on the argument that it protects tissue in the window when tissue is still salvageable
- **Mild-to-moderate Alzheimer’s and vascular dementia** — the older and, on balance, more positive part of the evidence base, with effects that are symptomatic rather than disease-modifying
- **Traumatic brain injury** — pooled trials report better Glasgow Coma and Outcome Scale scores, and no effect on mortality or length of stay
- **Post-stroke rehabilitation** — the neurorehabilitation groups in Romania and Austria are where most current research sits

What it is not used for, anywhere with an approval: healthy cognitive enhancement. No regulator has licensed it for that, and no trial has studied it for that.

### Who should avoid it

- Anyone with epilepsy or a history of status epilepticus — it is proconvulsant in some animal models, and this is a stated contraindication rather than a caution
- People with severe renal impairment — also a label contraindication, and consistent with the largest real-world reporting signal
- Anyone with hypersensitivity to any component, including the porcine-derived fraction
- Patients on antidepressants or MAO inhibitors without a prescriber adjusting doses — the interaction is additive
- Anyone considering an imported vial, which is the group this page is for: a porcine-brain-derived biological with no batch testing, self-administered, is a different risk profile from the one those 2,202 trial patients were in

## Route, dose and course

**Used for:** Stroke, dementia and traumatic brain injury — where it is licensed

**How it’s taken:** Intravenous infusion, diluted in saline and given over under an hour, as a daily course rather than a single dose. Intramuscular use appears in pediatric studies with no standardised schedule.

**Doses studied:** 20–50 mL daily in the stroke trials, most commonly 30 mL, for 10 to 21 days; dementia protocols run four to six weeks, sometimes repeated after a two-month gap.

**What the evidence shows:** Suggestive, not conclusive. Seven Cochrane reviews of acute ischaemic stroke have landed on the same verdict — low certainty, no clear harm — and the largest trial, CASTA, missed its primary endpoint.

**Legal status:** Approved in Austria, Germany, Russia, China, South Korea and roughly forty more countries. Not FDA-approved for anything, not on the 503A bulks list, not on the 503B nominated list. No US pharmacy is sanctioned to prepare or dispense it.

**What it costs:** Not published — Nothing to quote here. There is no US route, so there is no US price — and no provider we cover carries it.

Cerebrolysin is given intravenously in virtually every clinical context — diluted in saline and infused over less than an hour, as a course of daily doses rather than a single injection.

The protocols the trials used:

- **Stroke:** 20–50 mL daily, most commonly 30 mL, for 10 to 21 days, started as early after onset as possible
- **Dementia:** four to six weeks of infusions, sometimes repeated as a second course after a two-month gap
- **Vascular dementia:** the Phase 4 protocol used 20 mL daily, five days a week, across two four-week courses
- **Pediatric studies:** intramuscular, on schedules that were never standardised across studies

Two things are worth naming. Pharmacokinetics are not cleanly characterized, because what is being measured is not one molecule — half-life is not a well-defined number here, and the proposed mechanism is downstream induction rather than prolonged peptide presence. And there is no US route at all: not approved, so not dispensable; not on either compounding list, so not preparable. A prescriber here cannot write for it.

## The usual arc

**Read this first.** This is the shape of a supervised hospital course in a country where the drug is licensed — daily infusions, a defined number of days, a clinician watching. It is not a protocol anyone can follow in the US, and it is not what a self-administered gray-market course looks like.

Where it is licensed, cerebrolysin is a course rather than a regimen — days for stroke, weeks for dementia, then a stop. The arc below is the shape those courses take, and what the evidence does and does not say about each.

**DAY 1–10 The acute course** In the stroke trials, treatment starts as soon as possible after onset — within 12 hours in CASTA — and runs as a daily infusion for ten days or more. The proposed action is on the injured tissue in the window when it is still salvageable, which is why timing dominates the protocol.

**WEEK 4–6 The dementia course** Cognitive protocols run four to six weeks of infusions rather than days, and are often repeated as a second course after a two-month gap. Where benefit has been reported it is symptomatic and modest — better scores on global and cognitive scales, not a changed disease trajectory.

**MONTH 12+ Past the evidence** Nobody has established long-term outcomes beyond about a year, the best dosing schedule, or whether the drug adds anything to modern thrombolysis and thrombectomy. Those are the open questions, and they are the reason the Vienna-versus-Washington disagreement has not resolved.

## No provider we've verified carries Cerebrolysin yet

That is the honest answer, and it is not the same as "you can't have it". None of the
 licensed telehealth providers we track publishes Cerebrolysin, so there is
 no price to quote and no intake to send you to. Whether that changes depends on federal action rather than on us — which is why the next box
 exists rather than a button that goes nowhere.

### Tell me when someone carries it

### In the meantime

- [Peptides you can get today for the same goal](https://peptidestogo.com/tools/provider-match/)
- [Everything in Cognitive](https://peptidestogo.com/peptides/cognitive/)

## Questions we get about Cerebrolysin

### Is cerebrolysin FDA-approved?

No — not for any indication. It holds an FDA Orphan Drug Designation for frontotemporal dementia, which is a development incentive and is routinely misread as approval; it permits nothing to be marketed. Outside the US it is a different story: Austria, Germany, Russia, China, South Korea and roughly forty more countries license it, and neurologists in those systems have used it as adjunctive therapy for decades.

### Can I get cerebrolysin in the US?

Not lawfully through a pharmacy. It is not approved, and it is not on the 503A bulks list or the 503B nominated substances list, so no compounding pharmacy is sanctioned to prepare it. That is a cleaner regulatory line than most peptides have: there is no pathway, rather than an unresolved one. What exists instead is a gray-market import channel with no batch testing, for a biological product made from porcine brain tissue, usually self-administered.

### Does it work?

The honest answer depends on which trial you read. Seven Cochrane reviews of acute ischaemic stroke have reached the same verdict — uncertain functional benefit, low certainty of evidence, no clear harm — and CASTA, the largest trial at 1,070 patients, missed its primary endpoint, with benefit appearing only in a subgroup of more severe strokes. The dementia evidence is older, smaller and on balance more positive. What nobody disputes is that most of the positive trials were run in jurisdictions where the manufacturer had substantial influence over study design, and that independent replication has been limited.

### Is it safe?

This is the most consistent part of the record. A meta-analysis of 12 randomised trials and 2,202 patients found no statistically significant difference from placebo on deaths, serious adverse events or adverse events of any grade. The common events are mild and transient — dizziness most often, then headache, flushing, nausea, injection-site discomfort. It is contraindicated in epilepsy and in severe renal impairment, and it interacts additively with antidepressants and MAO inhibitors. The safety record applies to the manufactured product given by a clinician, which is not the same thing as an imported vial.

### Why has the manufacturer never sought FDA approval?

Nobody outside the company can answer that with certainty, but the structural reasons are not mysterious. A modern Phase 3 program that meets FDA standards is a very large investment; demonstrating efficacy for a structurally undefined biological mixture against current controls is genuinely hard; and the approved markets already generate revenue. None of that is evidence about whether the drug works. It explains why the question has stayed open for forty years.

We publish no medical reviewer by design. Every claim on this page traces to a
 source we hold on file, and the reviewed write-up with those citations lives on our
 hub.
[Read the full research on PeptideWellness ↗](https://peptidewellnessusa.com/peptides/cerebrolysin/)

## Related peptides